This article explores the current availability of GLP-1 medications in Canada, the legal and regulatory hurdles for U.S
The IRS eligibility test focuses on whether the medication was prescribed by a licensed provider for a qualifying medical condition, not on whether the medication is FDA-approved branded or pharmacy-compounded
Semaglutide also shows mild heart rate increases
PMID: 11533304
Some formulations bundle fenugreek, fructooligosaccharides, and various plant compounds, promoting them as 'natural GLP-1 alternatives.' Marketing images and testimonials often obscure the fact that these supplements have not been tested against semaglutide in head-to-head trials
Unlike semaglutide, which targets only the GLP-1 receptor, tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist simultaneously activating two key metabolic hormone pathways to produce an even more powerful effect on appetite suppression, fat metabolism, and blood sugar regulation